Diethylcarbamazine in the treatment of patients with onchocerciasis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.

1. Efficacy and safety of co-administered ivermectin plus albendazole for treating soil-transmitted helminths: A systematic review, meta-analysis and individual patient data analysis.PLoS neglected tropical diseases · 2018
   Pooled it
2. Onchocerca volvulus microfilariae in the anterior chambers of the eye and ocular adverse events after a single dose of 8 mg moxidectin or 150 µg/kg ivermectin: results of a randomized double-blind Phase 3 trial in the Democratic Republic of the Congo, Ghana and Liberia.Parasites & vectors · 2024
   Trial
3. Diagnosis of O. volvulus infection via skin exposure to diethylcarbamazine: clinical evaluation of a transdermal delivery technology-based patch.Parasites & vectors · 2015
   Trial
4. A randomized, single-ascending-dose, ivermectin-controlled, double-blind study of moxidectin in Onchocerca volvulus infection.PLoS neglected tropical diseases · 2014
   Trial
5. Identification of a moxidectin dose for 4- to 11-year-old children to support registration and potential use for onchocerciasis elimination: results of an open-label pharmacokinetic and safety study.Parasites & vectors · 2025
   Article
6. An Overview on Antifilarial Efficacy of Heterocyclic Motifs Encompassing Synthetic Strategies, SAR and Commercialized Medications.Current topics in medicinal chemistry · 2025
   Review
7. The pipeline for drugs for control and elimination of neglected tropical diseases: 2. Oral anti-infective drugs and drug combinations for off-label use.Parasites & vectors · 2023
   Review
8. Lymphatic Filariasis Elimination Status:Tropical medicine and infectious disease · 2023
   Article
9. Bma-LAD-2, an Intestinal Cell Adhesion Protein, as a Potential Therapeutic Target for Lymphatic Filariasis.mBio · 2022
   Article
10. Onchocerciasis drug development: from preclinical models to humans.Parasitology research · 2021
    Review
11. Intestinal UDP-glucuronosyltransferase as a potential target for the treatment and prevention of lymphatic filariasis.PLoS neglected tropical diseases · 2019
    Article
12. Potential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of Lymphatic Filariasis and Onchocerciasis in Africa.PLoS neglected tropical diseases · 2017
    Article
13. Research for new drugs for elimination of onchocerciasis in Africa.International journal for parasitology. Drugs and drug resistance · 2016
    Review
14. Unfulfilled potential: using diethylcarbamazine-fortified salt to eliminate lymphatic filariasis.Bulletin of the World Health Organization · 2007
    Article
15. Clinical picture and outcome of Serious Adverse Events in the treatment of Onchocerciasis.Filaria journal · 2003
    Article
16. Clinical pharmacokinetics in the treatment of tropical diseases. Some applications and limitations.Clinical pharmacokinetics · 1994
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as